Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

Amgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

CytomX Therapeutics, a Bay Area biotech firm with lucrative and high-profile partnerships in the industry, is laying off 40% ...

Amgen has been a biotechnology pioneer since 1980. The global pharma company's ongoing mission is "to serve patients" and one way to complete this mission is by keeping up-to-date with the latest ...